Cargando…

Treating Imatinib-Resistant Leukemia: The Next Generation Targeted Therapies

Imatinib (Gleevec/STI-571/CGP57148B, Novartis) is a small-molecule, tyrosine kinase inhibitor developed to target BCR-ABL, c-Kit, and PDGF-R. Through inhibition of these oncogenic kinases, imatinib is effective in the treatment of BCR–ABL—positive leukemia, gastrointestinal stromal tumor, and hypere...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burgess, Michael R., Sawyers, Charles L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	TheScientificWorldJOURNAL 2006
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917346/ https://www.ncbi.nlm.nih.gov/pubmed/16906325 http://dx.doi.org/10.1100/tsw.2006.184

Ejemplares similares

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009)

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
por: Swords, Ronan, et al.
Publicado: (2009)

Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)

Leptin modification in chronic myeloid leukemia patients treated with imatinib: An emerging effect of targeted therapy.()
por: Mariani, Stefania, et al.
Publicado: (2013)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
por: Kumar, Rahul, et al.
Publicado: (2020)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
por: Chandra, Abhilash, et al.
Publicado: (2020)

Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
por: Bitencourt, Roberta, et al.
Publicado: (2011)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib
por: Breccia, Massimo, et al.
Publicado: (2008)

Imatinib: A Breakthrough of Targeted Therapy in Cancer
por: Iqbal, Nida, et al.
Publicado: (2014)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Nanoparticle Formulations of siRNA: The Next Generation of Targeted Therapy for Lymphomas and Leukemias?
por: Wang, Andrew Z.
Publicado: (2014)

Next-Generation Sequencing in Acute Lymphoblastic Leukemia
por: Coccaro, Nicoletta, et al.
Publicado: (2019)

Concomitant ATM Mutations Identified by Next Generation Sequencing in a Patient With New-Onset Acute Myeloid Leukemia Following Imatinib Treatment for Chronic Myeloid Leukemia
por: Stein, Matthew K., et al.
Publicado: (2018)

Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
por: Simões, Belinda Pinto, et al.
Publicado: (2011)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
por: Bilajac, Esma, et al.
Publicado: (2022)

Next-generation strategy for treating drug resistant bacteria: Antibiotic hybrids
por: Gupta, Varsha, et al.
Publicado: (2019)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
por: Lee, Jae Wook, et al.
Publicado: (2011)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
por: Mashhadi, Mohammad Ali, et al.
Publicado: (2014)

The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia
por: Zhu, Yu, et al.
Publicado: (2016)

Integration of Next-Generation Sequencing to Treat Acute Lymphoblastic Leukemia with Targetable Lesions: The St. Jude Children’s Research Hospital Approach
por: Inaba, Hiroto, et al.
Publicado: (2017)

Resistance to targeted therapies in acute myeloid leukemia
por: Mecklenbrauck, Rabea, et al.
Publicado: (2022)

Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance
por: Carew, Jennifer S, et al.
Publicado: (2008)

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
por: Kavanagh, Simon, et al.
Publicado: (2018)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
por: Conchon, Monika, et al.
Publicado: (2011)

Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature
por: Amouei, Asiyeh, et al.
Publicado: (2021)

RAPID CONVERSION OF CHRONIC MYELOID LEUKEMIA TO CHRONIC MYELOMONOCYTIC LEUKEMIA IN A PATIENT ON IMATINIB THERAPY
por: Khorashad, Jamshid S., et al.
Publicado: (2016)

Overexpression of P‐glycoprotein and resistance to Imatinib in chronic myeloid leukemia patients
por: Ammar, Mariam, et al.
Publicado: (2020)

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
por: Abou Dalle, Iman, et al.
Publicado: (2019)

Targeting Leukemia-Initiating Cells and Leukemic Niches: The Next Therapy Station for T-Cell Acute Lymphoblastic Leukemia?
por: Zhang, Ziting, et al.
Publicado: (2022)

Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches
por: Valent, Peter
Publicado: (2007)

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
por: Martinelli, Giovanni, et al.
Publicado: (2007)

Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?
por: Tolle, Fabrice, et al.
Publicado: (2021)

Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors
por: Masucci, Maria Teresa, et al.
Publicado: (2023)

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2014)

Diuretic-Resistant Ascites Following Laparoscopic Surgery in a Patient With Chronic Myeloid Leukemia on Imatinib Therapy
por: Pappa, Efthymia, et al.
Publicado: (2021)

Gynecomastia in a Boy with Chronic Myeloid Leukemia during Imatinib Therapy
por: Tavil, Betül, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_nauqq44dj1l00riktr8smnve7e